- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Oliver Dorigo on Identified Biomarkers in Gynecologic Malignancies
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies, said Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies, said Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Transcript
What biomarkers have you identified to determine prognosis and treatment outcomes in gynecologic malignancies?
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies. PARP inhibitors, for example, work the best in those patients that have either germline mutations of BRCA1 and BRCA2 or those mutations only in the tumor tissue. It’s particularly true in ovarian cancer, where we have the most experience.
We also know that certain ovarian cancers have a certain degree of defects and repair mechanisms that the cell uses to repair DNA damage. If these mechanisms are dysfunctional, then patients, again, are more likely to respond to PARP inhibitors. We call this a so-called homologous recombination deficiency score, which is a measure or a biomarker that predicts the response to PARP inhibitors, at least to some extent.
In immunotherapy, biomarkers relate mostly to what we call microsatellite instability, which does increase the probability of a patient responding to immune-checkpoint inhibition.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
